A significant body of evidence exists suggesting a role for metformin, a known activator of AMPK (Section 4.2), in reduced survival or inhibition of growth of cancer stem cells, as well as inhibition of their differentiation potential and expression of stemness markers [165,166,167,168,169,170,171]. This evidence concerns the gene PRKAA2 and cancer.